María Carmen Chillón-rekin lankidetzan egindako argitalpenak (50)

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  2. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2020

  1. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  2. Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

    Blood Cancer Journal, Vol. 10, Núm. 10

2017

  1. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma

    Journal of Molecular Diagnostics, Vol. 19, Núm. 1, pp. 99-106

  2. Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array

    Hematological Oncology, Vol. 35, Núm. 4, pp. 746-751

2015

  1. Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: Phase Ib/II panobidara study

    Haematologica, Vol. 100, Núm. 10, pp. 1294-1300

  2. The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution

    Leukemia

2014

  1. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

    Leukemia, Vol. 28, Núm. 2, pp. 391-397

2013

  1. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  2. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

  3. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia

    Leukemia, Vol. 27, Núm. 8, pp. 1722-1728

  4. The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma

    Annals of Hematology, Vol. 92, Núm. 1, pp. 97-100

2012

  1. Kappa deleting element as an alternative molecular target for minimal residual disease assessment by real-time quantitative PCR in patients with multiple myeloma

    European Journal of Haematology, Vol. 89, Núm. 4, pp. 328-335

  2. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: Antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1879-1888

  3. Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival

    Annals of Hematology, Vol. 91, Núm. 12, pp. 1887-1895

2011

  1. Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain)

    Tissue Antigens, Vol. 78, Núm. 4, pp. 249-255

  2. Upregulation of dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients

    Haematologica, Vol. 96, Núm. 3, pp. 468-471

2010

  1. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)

    Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458

  2. Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling

    Leukemia, Vol. 24, Núm. 3, pp. 629-637